Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc.（TERN）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · TERN · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
14
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Terns Pharmaceuticals, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
TERN 季度内部人买卖趋势
TERN 内幕交易卖出 · TERN 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · TERN CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
TERN 高管卖出股份 · TERN 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 5, 2026 | Kuriakose Emil Chief Medical Officer | Other | 24,562 | $1.30M⚡ | Form 4 |
| May 5, 2026 | Kuriakose Emil Chief Medical Officer | Other | 81,953 | $4.34M⚡ | Form 4 |
| May 5, 2026 | Gengos Andrew CFO | Other | 40,503 | $2.15M⚡ | Form 4 |
| May 5, 2026 | Gengos Andrew CFO | Other | 68,750 | $3.64M⚡ | Form 4 |
| May 5, 2026 | Burroughs Amy L. CEO · Director | Other | 8,319 | $441K | Form 4 |
| May 5, 2026 | Burroughs Amy L. CEO · Director | Other | 150,000 | $7.95M⚡ | Form 4 |
| Apr 1, 2026 | Kuriakose Emil Chief Medical Officer | Sale | 942 | $50K | Form 4 |
| Mar 16, 2026 | Burroughs Amy L. CEO · Director | Option | 14,583 | $68K | Form 4 |
| Mar 16, 2026 | Burroughs Amy L. CEO · Director | Sale | 11,813 | $550K | Form 4 |
| Mar 16, 2026 | Burroughs Amy L. CEO · Director | Sale | 2,770 | $131K | Form 4 |
| Feb 17, 2026 | Burroughs Amy L. CEO · Director | Option | 14,583 | $68K | Form 4 |
| Feb 17, 2026 | Burroughs Amy L. CEO · Director | Sale | 2,341 | $89K | Form 4 |
| Feb 17, 2026 | Burroughs Amy L. CEO · Director | Sale | 8,159 | $320K | Form 4 |
| Feb 17, 2026 | Burroughs Amy L. CEO · Director | Sale | 4,083 | $163K | Form 4 |
| Jan 14, 2026 | Kuriakose Emil Chief Medical Officer | Award | 56,250 | — | Form 4 |
| Jan 14, 2026 | Gengos Andrew CFO | Award | 68,750 | — | Form 4 |
| Jan 15, 2026 | Burroughs Amy L. CEO · Director | Option | 14,583 | $68K | Form 4 |
| Jan 15, 2026 | Burroughs Amy L. CEO · Director | Option | 27,083 | $126K | Form 4 |
| Jan 15, 2026 | Burroughs Amy L. CEO · Director | Option | 27,083 | $126K | Form 4 |
| Jan 15, 2026 | Burroughs Amy L. CEO · Director | Sale | 61,228 | $2.27M⚡ | Form 4 |
| Jan 15, 2026 | Burroughs Amy L. CEO · Director | Sale | 7,521 | $282K | Form 4 |
| Jan 14, 2026 | Burroughs Amy L. CEO · Director | Award | 150,000 | — | Form 4 |
| Jan 5, 2026 | Burroughs Amy L. CEO · Director | Option | 150,000 | — | Form 4 |
| Jan 5, 2026 | Burroughs Amy L. CEO · Director | Sale | 71,339 | $2.72M⚡ | Form 4 |
| Jan 2, 2026 | Burroughs Amy L. CEO · Director | Option | 21,551 | $100K | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 TERN 内幕交易
TERN 内幕交易
Terns Pharmaceuticals, Inc.（TERN）内幕交易数据来源于公司内部人（包括Burroughs Amy L. (CEO · Director), Kuriakose Emil (Chief Medical Officer), Gengos Andrew (CFO)）提交的SEC Form 4申报文件。过去12个月内，4位内部人向SEC提交了交易申报。TERN内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Terns Pharmaceuticals, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
TERN 内幕交易 · 5个问题Terns Pharmaceuticals, Inc.（TERN）的内部人包括高管和董事，如Burroughs Amy L. (CEO · Director), Kuriakose Emil (Chief Medical Officer), Gengos Andrew (CFO)等。过去12个月内，4位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026